Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Novartis Pharmaceuticals · 2025
ClinicalTrials.gov · Datasets · License: Public Domain · 2025
Open Source ↗
agemrims
relapsing multiple sclerosis, ms, rms, remibrutinib, lou064, ocrelizumab, age, mri, t2 lesions, neda-3, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 810507
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.